Bicycle Therapeutics plc

(NASDAQ:BCYC)

Latest On Bicycle Therapeutics plc (BCYC):

Date/Time Type Description Signal Details
2023-05-14 14:15 ESTNewsBicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs YetN/A
2023-05-10 11:38 ESTNewsBicycle stock jumps on pact with Bayer to develop radiopharmaceuticals for cancerN/A
2023-05-04 21:13 ESTNewsBicycle Therapeutics GAAP EPS of -$1.30, revenue of $4.89MN/A
2023-03-28 17:17 ESTNewsBicycle stock pops on cancer drug discovery pact with Novartis, gets $50M upfrontN/A
2023-02-28 15:09 ESTNewsBicycle Therapeutics GAAP EPS of -$1.01 beats by $0.05, revenue of $3.19M misses by $0.56MN/A
2023-02-14 18:15 ESTNewsBicycle Therapeutics posts Phase 1 data for cancer candidateN/A
2023-01-04 15:09 ESTNewsBicycle Therapeutics adds 10% on FDA’s fast track tag for bladder cancer therapyN/A
2022-11-03 21:35 ESTNewsBicycle Therapeutics GAAP EPS of -$0.96 misses by $0.05, revenue of $3.04M misses by $2.54MN/A
2022-10-08 01:53 ESTNewsBicycle Therapeutics: Exploring An Intriguing Developmental PlatformN/A
2022-09-01 00:39 ESTNewsBicycle Therapeutics initiated Outperform at Cowen citing drug platformN/A
2022-08-04 22:13 ESTNewsBicycle Therapeutics GAAP EPS of -$0.90 misses by $0.04, revenue of $4.38M beats by $0.69MN/A
2022-07-12 21:29 ESTNewsBicycle to get $10M as Genentech uses option for new program under cancer drug collaborationN/A
2022-07-06 01:28 ESTNewsBicycle Therapeutics: Promising Early-Stage Cancer Drug DeveloperN/A
2022-05-05 19:05 ESTNewsBicycle Therapeutics GAAP EPS of -$0.93 misses by $0.26, revenue of $3.86M misses by $0.55MN/A
2022-04-17 04:20 ESTNewsBicycle Therapeutics: Trying To Catch This Falling KnifeN/A
2022-04-11 15:59 ESTNewsBicycle Therapeutics down 33% after rising sharply on Friday on bladder cancer dataN/A
2022-04-11 15:59 ESTNewsBicycle Therapeutics presents at AACR Annual Meeting 2022 - SlideshowN/A
2022-04-09 02:28 ESTNewsBicycle Therapeutics gains on early-stage data for oncology asset in bladder cancerN/A
2022-03-27 00:04 ESTNewsBicycle Therapeutics: A Buy Ahead Of AACR PresentationN/A
2022-03-01 19:32 ESTNewsBicycle Therapeutics GAAP EPS of -$0.63 beats by $0.01, revenue of $3.77M misses by $1.11MN/A
2022-02-28 05:43 ESTNewsBicycle Therapeutics: An Oncology Play With Big PotentialN/A
2022-01-05 15:44 ESTNewsBicycle Therapeutics COO transitions to CTO; provides clinical program updatesN/A
2021-11-10 00:38 ESTNewsBicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is NextN/A
2021-11-04 23:17 ESTNewsBicycle Therapeutics gets dosing underway in early-stage BT7480 cancer trialN/A
2021-11-04 23:17 ESTNewsBicycle Therapeutics EPS beats by $0.03, misses on revenueN/A
2021-10-26 09:10 ESTNewsGenentech exercises option for new immuno-oncology program with Bicycle TherapeuticsN/A
2021-10-13 15:17 ESTNewsBicycle Therapeutics prices upsized ADS offering at $54N/A
2021-10-12 18:51 ESTNewsBicycle Therapeutics falls 5% on proposed ADS offeringN/A
2021-10-08 21:15 ESTNewsBicycle Therapeutics draws higher price targets from analysts after cancer study dataN/A
2021-10-08 01:35 ESTNewsBicycle's shares rise as early-stage candidate shows preliminary anti-tumor activity (updated)N/A
2021-08-25 11:00 ESTNewsBicycle Therapeutics: Scaffolding Short Linear Peptides Into BicyclesN/A
2021-08-05 20:10 ESTNewsBicycle Therapeutics EPS misses by $0.02, misses on revenueN/A
2021-07-22 16:37 ESTNewsIonis inks licensing deal with Bicycle Therapeutics to advance LICA technologyN/A
2021-05-07 01:50 ESTNewsBicycle Therapeutics EPS misses by $0.05, beats on revenueN/A
2021-03-18 11:26 ESTAnalyst RatingThe Analyst Target Price has increased from $34.88 to $36.75.Buy
2021-03-13 18:12 ESTFinancialsCompany financials have been released.Neutral
2021-03-12 13:59 ESTEarnings EstimateAn EPS average of -$3.34 is estimated for the 2022 year.Sell
2021-03-12 13:59 ESTEarnings EstimateAn EPS average of -$0.59 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-11 21:22 ESTNewsBicycle Therapeutics EPS misses by $0.32, beats on revenueN/A
2021-01-21 14:38 ESTAnalyst RatingThe Analyst Target Price has increased from $31.38 to $34.88.Buy
2021-01-18 06:16 ESTAnalyst RatingThe Analyst Target Price has increased from $27.75 to $31.38.Buy
2021-01-14 14:35 ESTNewsBicycle Therapeutics gives out pipeline update, shares riseN/A
2020-12-04 19:08 ESTFinancialsCompany financials have been released.Neutral
2020-12-04 10:53 ESTAnalyst RatingThe Analyst Target Price has increased from $27.38 to $27.75.Buy
2020-12-02 13:28 ESTNewsBicycle Therapeutics settles IP dispute with PepscanN/A
2020-11-27 00:34 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 15:35 ESTAnalyst RatingThe Analyst Target Price has decreased from $27.75 to $27.38.Neutral
2020-11-06 23:03 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 10:34 ESTEarnings EstimateAn EPS average of -$0.54 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-06 10:34 ESTAnalyst RatingThe Analyst Target Price has increased from $25.5 to $27.75.Buy

About Bicycle Therapeutics plc (BCYC):

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

BCYC Quotes by TradingView

See Advanced Chart

General

  • Name Bicycle Therapeutics plc
  • Symbol BCYC
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 87
  • Fiscal Year EndDecember
  • IPO Date2019-05-23
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.bicycletherapeutics.com
View More

Valuation

  • Trailing PE 1839
  • Price/Sales (Trailing 12 Mt.) 52
  • Price/Book (Most Recent Quarter) 6.83
  • Enterprise Value Revenue 51.14
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.92
  • Next Year EPS Estimate -$3.38
  • Next Quarter EPS Estimate -$0.60
  • Operating Margin -500%
  • Return on Assets -24%
  • Return on Equity -54%
  • Revenue 10.39 million
  • Earnings Per Share -$14.16
  • Revenue Per Share $0.54
  • Gross Profit -22759000
  • Quarterly Earnings Growth -27.1%
View More

Highlights

  • Market Capitalization 618.36 million
  • EBITDA -24381000
  • PE Ratio -6.18
  • Analyst Target Price $36.75
  • Book Value Per Share $5.33
View More

Share Statistics

  • Shares Outstanding 23.09 million
  • Shares Float 14.83 million
  • % Held by Insiders 2990%
  • % Held by Institutions 42.85%
  • Shares Short 400080
  • Shares Short Prior Month 397139
  • Short Ratio 2.76
  • Short % of Shares Outstanding 2%
View More

Technicals

  • 52 Week High $33
  • 52 Week Low $10.5
  • 50 Day Moving Average 26.66
  • 200 Day Moving Average 21.57
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Bicycle Therapeutics plc (BCYC) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Bicycle Therapeutics plc (BCYC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.83-$0.41-101.6%
2020-09-302020-11-05$N/A-$0.52-$0.531.89%
2020-06-302020-08-05$N/A-$0.67-$0.46-45.02%
2020-03-312020-05-07$N/A-$0.63-$0.38-64.36%
2019-12-312020-03-10$5.28 million-$0.25-$0.5251.62%
2019-09-302019-11-07$614000-$0.53-$0.7023.74%
2019-06-302019-08-08$1.52 million-$0.66-$0.62-6.45%
2019-03-312019-05-23$6.38 million-$0.49

Bicycle Therapeutics plc (BCYC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Bicycle Therapeutics plc (BCYC) Chart:

Bicycle Therapeutics plc (BCYC) News:

Below you will find a list of latest news for Bicycle Therapeutics plc (BCYC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Bicycle Therapeutics plc (BCYC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-07-1710CALL0 2250TRUE00
2026-07-1720CALL0 0489.04TRUE00
2026-07-1730CALL0 0933.93TRUE00
2026-07-1740CALL0 15170TRUE00
2026-07-1750CALL0 255114.2FALSE00
2026-07-1760CALL0 11358.01FALSE00
2026-07-1770CALL0 1285.92FALSE00
2026-07-1780CALL0 11493.7FALSE00
2026-07-1790CALL0 00FALSE00
2026-07-1710.2PUT1 01120.2FALSE0.20
2026-07-1720PUT0 01479.91FALSE00
2026-07-1730PUT0 0233.02FALSE00
2026-07-1740PUT0 122987.84FALSE00
2026-07-1750PUT0 0947.23TRUE00
2026-07-1760PUT0 0592.21TRUE00
2026-07-1770PUT0 0330.94TRUE00
2026-07-1780PUT0 0388.04TRUE00
2026-07-1790PUT0 0435.67TRUE00
2026-08-2110CALL0 00TRUE00
2026-08-2120CALL0 0183.52TRUE00
2026-08-2130CALL0 0356.18TRUE00
2026-08-2140CALL0 0432.97TRUE00
2026-08-2150CALL0 5240.36FALSE00
2026-08-2160CALL0 0261.73FALSE00
2026-08-2170CALL0 0285.56FALSE00
2026-08-2180CALL0 0311.36FALSE00
2026-08-2110PUT0 00FALSE00
2026-08-2120PUT0 00FALSE00
2026-08-2130PUT0 10100.72FALSE00
2026-08-2140.21PUT20 88851.63FALSE0.010.05
2026-08-2150PUT0 0364.55TRUE00
2026-08-2160PUT0 0228.88TRUE00
2026-08-2170PUT0 0130.52TRUE00
2026-08-2180PUT0 0153.15TRUE00
2026-09-1810CALL0 00TRUE00
2026-09-1820CALL0 0108.85TRUE00
2026-09-1830CALL0 52273.89TRUE00
2026-09-1840CALL0 0333.23TRUE00
2026-09-1850.3CALL33 27565.74FALSE0.30
2026-09-1860CALL0 66663.81FALSE00
2026-09-1870CALL0 1389.78FALSE00
2026-09-1880CALL0 0142.35FALSE00
2026-09-1890CALL0 0282.31FALSE00
2026-09-18100CALL0 1468.07FALSE00
2026-09-18110CALL0 0479.64FALSE00
2026-09-18120CALL0 1296.72FALSE00
2026-09-18130CALL0 119499.21FALSE00
2026-09-1810PUT0 00FALSE00
2026-09-1820PUT0 0447.39FALSE00
2026-09-1830PUT0 192678.04FALSE00
2026-09-1840.3PUT0 108548.31FALSE00
2026-09-1850PUT0 24429.95TRUE00
2026-09-1860PUT0 0177.82TRUE00
2026-09-1870PUT0 0102.77TRUE00
2026-09-1880PUT0 097.83TRUE00
2026-09-1890PUT0 0111.67TRUE00
2026-09-18100PUT0 0123.72TRUE00
2026-09-18110PUT0 0112.25TRUE00
2026-09-18120PUT0 0144TRUE00
2026-09-18130PUT0 0152.74TRUE00
2026-12-1810CALL0 0126.64TRUE00
2026-12-1820CALL0 4758.92TRUE00
2026-12-1830CALL0 2178.44TRUE00
2026-12-1840CALL0 3217.73TRUE00
2026-12-1850CALL0 741154.19FALSE00
2026-12-1860CALL0 0161.74FALSE00
2026-12-1870CALL0 0171.39FALSE00
2026-12-1880CALL0 5180.13FALSE00
2026-12-1890CALL0 0186.72FALSE00
2026-12-18100CALL0 3196.04FALSE00
2026-12-1810PUT0 00FALSE00
2026-12-1820PUT0 1083.03FALSE00
2026-12-1830PUT0 82861.49FALSE00
2026-12-1840PUT0 645.42FALSE00
2026-12-1850PUT0 0127.26TRUE00
2026-12-1860PUT0 0102.31TRUE00
2026-12-1870PUT0 071.48TRUE00
2026-12-1880PUT0 077.36TRUE00
2026-12-1890PUT0 067.34TRUE00
2026-12-18100PUT0 00TRUE00

Latest BCYC Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST200$13.335
Jun 13, 2022 7:59 PM EST200$13.335
Jun 13, 2022 7:59 PM EST17$13.33
Jun 13, 2022 7:59 PM EST975$13.3
Jun 13, 2022 7:59 PM EST200$13.36

Bicycle Therapeutics plc (BCYC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920077995/0001104659-20-077995-index.htm
2020-06-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1761612/000000000020005156/0000000000-20-005156-index.htm
2020-09-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000089914020000427/0000899140-20-000427-index.htm
2020-07-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1761612/000092963820000753/0000929638-20-000753-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1761612/000104746920002601/0001047469-20-002601-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919060061/0001104659-19-060061-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919060805/0001104659-19-060805-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919062674/0001104659-19-062674-index.htm
2019-11-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919065673/0001104659-19-065673-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465919075599/0001104659-19-075599-index.htm
2020-01-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920008696/0001104659-20-008696-index.htm
2020-02-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920010545/0001104659-20-010545-index.htm
2020-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920024459/0001104659-20-024459-index.htm
2020-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920027088/0001104659-20-027088-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920030969/0001104659-20-030969-index.htm
2020-03-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920031393/0001104659-20-031393-index.htm
2020-04-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920043974/0001104659-20-043974-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920057711/0001104659-20-057711-index.htm
2020-06-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1761612/000110465920070493/0001104659-20-070493-index.htm
2020-06-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1761612/000110465920072426/0001104659-20-072426-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920077995/0001104659-20-077995-index.htm
2020-07-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920083108/0001104659-20-083108-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920090550/0001104659-20-090550-index.htm
2020-08-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1761612/000110465920090870/0001104659-20-090870-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920110716/0001104659-20-110716-index.htm
2020-10-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1761612/000110465920111698/0001104659-20-111698-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920111705/0001104659-20-111705-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1761612/000110465920121565/0001104659-20-121565-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051098/0001209191-19-051098-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051100/0001209191-19-051100-index.htm
2019-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119051101/0001209191-19-051101-index.htm
2019-11-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119055217/0001209191-19-055217-index.htm
2019-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919119061400/0001209191-19-061400-index.htm
2020-01-064/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001912/0001209191-20-001912-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001917/0001209191-20-001917-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001921/0001209191-20-001921-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001925/0001209191-20-001925-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001930/0001209191-20-001930-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001944/0001209191-20-001944-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001967/0001209191-20-001967-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001981/0001209191-20-001981-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120001990/0001209191-20-001990-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002003/0001209191-20-002003-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002011/0001209191-20-002011-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120002019/0001209191-20-002019-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120012510/0001209191-20-012510-index.htm
2020-04-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120024640/0001209191-20-024640-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025811/0001209191-20-025811-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025812/0001209191-20-025812-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025813/0001209191-20-025813-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025816/0001209191-20-025816-index.htm
2020-04-274/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120025817/0001209191-20-025817-index.htm
2020-08-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120047523/0001209191-20-047523-index.htm
2020-08-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000120919120048252/0001209191-20-048252-index.htm
2020-02-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1761612/000138713120001831/0001387131-20-001831-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1761612/000138713120008376/0001387131-20-008376-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837019010277/0001558370-19-010277-index.htm
2020-03-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1761612/000155837020002278/0001558370-20-002278-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020005538/0001558370-20-005538-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020009277/0001558370-20-009277-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1761612/000155837020012697/0001558370-20-012697-index.htm
2020-06-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1761612/999999999520001433/9999999995-20-001433-index.htm

Bicycle Therapeutics plc (BCYC) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bicycle Therapeutics plc (BCYC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2990%
Institutional Ownership: 4285%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-04-14Gregory Paul WinterDirectorBuy71,450.00163,927.00https://www.sec.gov/Archives/edgar/data/1761612/000120919120024640/0001209191-20-024640-index.htm